Source: Pharamceutical Technology

Fulgent Pharma : Paclitaxel by Fulgent Pharma for Nasopharyngeal Cancer: Likelihood of Approval

Paclitaxel is under clinical development by Fulgent Pharma and currently in Phase II for Nasopharyngeal Cancer.

Read full article »
Fulgent Pharma 's Competitors | Fulgent Pharma 's News | Fulgent Pharma 's Financials
Stay up-to-date with the latest news on Fulgent Pharma
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Ray Yin's photo - President of Fulgent Pharma

President

Ray Yin

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Fulgent Pharma